Solange Peters, MD, PhD of Lausanne University Hospital gives an overview of her presentation, Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage IV or recurrent non-small cell lung cancer: an exploratory analysis of CheckMate -026, which was discussed at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
CheckMate-026: Impact of Tumor Mutation Burden on Nivolumab in Non-Small Cell Lung Cancer
